Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Gynecologic oncology - 1 Feb 2017

Spreafico A, Oza A M, Clarke B A, Mackay H J, Shaw P, Butler M, Dhani N C, Lheureux S, Wilson M K, Welch S, Zhang T, Yu C, Stockley T, Siu L L, Kamel-Reid S, Bedard P L

Abstract excerpt

BACKGROUND: Genomic alterations that activate the MAPK signaling pathway frequently occur in Type I Epithelial Ovarian Cancers (EOCs). We evaluated therapeutic response outcomes in patients with type I EOC treated with genotype-matched therapy on clinical trials enrolled in a prospective molecular profiling program. MATERIAL AND METHODS: Formalin fixed paraffin embedded tumor tissues were prospectively screened...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CA-125 Antigen
Share to Carcinoma, Ovarian Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to GTP Phosphohydrolases

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasms, Glandular and Epithelial

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 28062115
DOI: 10.1016/j.ygyno.2016.12.002

Genes

KRAS
NRAS
BRAF
CTNNB1
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).PMID 28062115Read ↗

Clinical Outcomes of Genotype-Matched Therapy For Recurrent Gynecological CancersSemantic proximity Read ↗

Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.Semantic proximity Read ↗

Molecular diagnosis in type I epithelial ovarian cancer.Semantic proximity Read ↗

Genetic alterations and their therapeutic implications in epithelial ovarian cancer.Semantic proximity Read ↗

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.Semantic proximity Read ↗

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read ↗

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.Semantic proximity Read ↗

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.Semantic proximity Read ↗

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Semantic proximity Read ↗

Dissecting “PI3Kness”: The Complexity of Personalized Therapy for Ovarian CancerSemantic proximity Read ↗

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.Semantic proximity Read ↗

IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.